Moderna’s phase 2-3 clinical trials showed that the mRNA-1345 vaccine is effective in preventing RSV in adults over 60. The study also found no safety concerns. An estimated 5.2 million RSV cases in 2019 led to significant hospitalizations and deaths in this age group. The vaccine demonstrated efficacy in preventing RSV-associated lower respiratory tract disease and acute respiratory disease. Adverse reactions were mild to moderate. The study authors noted the growing need for an RSV vaccine as the global population ages. External commenters highlighted the importance of a potential RSV vaccine and the need for analysis of vaccine protection over subsequent RSV seasons.
Source link
Moderna’s mRNA-based RSV vaccine safe, effective for older adults
